Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares 1 3 Year Treasury Bond ETF (SHY) vs GeneDx Holdings Corp (WGS) Price & Performance

iShares 1 3 Year Treasury Bond ETFTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

iShares 1 3 Year Treasury Bond ETF vs GeneDx Holdings Corp — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.67, while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: GeneDx Holdings Corp is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

SHYWGS
Sector
Fixed IncomeTechnology
52-Week High
$83.18$167.51
52-Week Low
$81.59$34.51
Market Cap
$2.56B
Enterprise Value
$2.60B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares 1 3 Year Treasury Bond ETF

SHY is currently trading at $81.66, showing minimal daily movement with a slight decline of 0.04%. The technical picture appears bearish with moving averages signaling caution, though oscillators suggest some buying opportunity. Recent corporate actions include consistent dividend payments scheduled through mid-2026, providing income stability for shareholders amid market volatility.

The outlook for SHY reflects mixed signals with technical indicators showing bearish momentum but potential oversold conditions. Investment opportunities include dividend income stability, while risks center on broader bond market volatility and interest rate sensitivity. The stock faces headwinds from rising Treasury yields and inflation concerns that could pressure fixed-income investments.

GeneDx Holdings Corp

WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.

Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares 1 3 Year Treasury Bond ETF

SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.

Read more on SHY

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS